Notice of Pre-AIA or AIA Status
The present application, filed on or after
March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claims 1-13 are pending in the instant application.
Election/Restrictions
Applicant’s election without traverse of the species of Compound No. 1, claimed in instant claim 8 (also disclosed as Example 1 on page 108 of the instant specification),
PNG
media_image1.png
260
612
media_image1.png
Greyscale
in the reply filed on December 31, 2025 is acknowledged. The requirement is still deemed proper and is therefore made FINAL.
Applicant’s claimed compound genus has a number of variables and their permutations and combinations result in a vast number of compounds that are generically claimed. In an initial attempt to examine a broad scope of compounds embraced by instant claim 1, over 83,200 Chemical Abstract Registry numbers were recovered in one database search alone.
PNG
media_image2.png
62
400
media_image2.png
Greyscale
Therefore, the claimed products in the instant application will be examined according to MPEP §803.02.
The instant product claims have been examined to the extent that they are readable on the elected species of Compound No. 1. Since no prior art was found on the elected species, the examination was expanded within the compound genus until prior art was found, in which case, the examination stopped and prior art has been applied against the claims. Note, MPEP §803.02. The subject matter of the expanded search and examination thus far, inclusive of the elected species of Compound No. 1, is as follows:
a compound of instant Formula 1,
PNG
media_image3.png
176
206
media_image3.png
Greyscale
or a tautomer, a pharmaceutically acceptable salt, a hydrate, a solvate or a stereoisomer thereof,
wherein
W1 represents CRa;
W2 represents CRb;
W3 represents CRc;
W4 represents CRd;
W5 represents N;
W6 represents N;
W7 represents N;
(W1--W7 are defined to make up a benzotriazole
ring)
Z is absent;
R5 represents -A-(R6)y;
A represents a substituted or unsubstituted
piperidine (i.e., a C5 heterocyclic group); and
all other variables are as defined in instant independent claim 1.
Subject matter not embraced by the above identified expanded search and examination is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on
December 31, 2025.
Priority
Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55.
Information Disclosure Statement
The Examiner has considered the Information Disclosure Statement filed on July 28, 2023. The submission is in compliance with the provisions of
37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Specification
The title of the invention is not in accordance with MPEP §606 (reproduced below in-part) since the word “Novel” is found in the title.
606 Title of Invention [R-10.2019]
37 C.F.R. 1.72 Title and abstract.
(a) The title of the invention may not exceed 500 characters in length and must be as short and specific as possible. Characters that cannot be captured and recorded in the Office’s automated information systems may not be reflected in the Office’s records in such systems or in documents created by the Office. Unless the title is supplied in an application data sheet (§ 1.76 ), the title of the invention should appear as a heading on the first page of the specification.
*****
The title of the invention should be placed at the top of the first page of the specification unless it is provided in the application data sheet (see 37 CFR 1.76 ). The title should be brief but technically accurate and descriptive and should contain fewer than 500 characters.
The words listed below are not considered as part of the title of an invention, these words should not be included at the beginning of the title of the invention and will be deleted when the Office enters the title into the Office’s computer records, and when any patent issues. The term "new" will not be deleted when it is a part of a proper name, such as "New York". Similarly, the term "design" will not be deleted when it is a part of a term, such as "Design-aiding apparatus...".
The words listed below are not considered as part of the title of an invention:
A, An, The, Improved, Improvement(s) in/for/of, New, Novel, Related to, Design, Design for/of (a), Ornamental design, and Ornamental.
It is suggested that “NOVEL” be deleted from the title.
The disclosure is objected to because of the following informalities: the chemical structures in the reaction schemes on pages 91-93 are not all completely legible.
Appropriate correction is required.
Specification
The disclosure is objected to because of the following informalities:
the Preliminary Amendment filed July 28, 2023 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure.
35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: the sentence “The entire contents of these applications is incorporated herein by reference.”
MPEP 211.02 and MPEP 201.06(c)(IV) state the following in regard to “Incorporation by Reference” and PCT Rule 20.6, Rule 20.7 and Rule 4.18 are directed specifically to International applications:
MPEP 211.02, in-part
For applications filed on or after September 21, 2004, a claim under 35 U.S.C. 119(e) or 120 and 37 CFR 1.78 for benefit of a prior-filed provisional application, nonprovisional application, international application designating the United States, or international design application designating the United States that was present on the filing date of the continuation or divisional application, or the nonprovisional application claiming benefit of a prior-filed provisional application, is considered an incorporation by reference of the prior-filed application as to inadvertently omitted material, subject to the conditions and requirements of 37 CFR 1.57(b). The purpose of 37 CFR 1.57(b) is to provide a safeguard for applicants when all or a portion of the specification and/or drawing(s) is (are) inadvertently omitted from an application. See MPEP § 201.06 and 217. However, applicants are encouraged to provide in the specification an explicit incorporation by reference statement to the prior-filed application(s) for which benefit is claimed under 35 U.S.C. 119(e) or 120 if applicants do not wish the incorporation by reference to be limited to inadvertently omitted material pursuant to 37 CFR 1.57(b). See 37 CFR 1.57(c). See also MPEP §§ 217 and MPEP § 608.01(p).
When a benefit claim is submitted after the filing of an application, and the later-filed application as filed did not incorporate the prior-filed application by reference, applicant cannot add an incorporation by reference statement of the prior application. An incorporation by reference statement added after an application’s filing date is not effective because no new matter can be added to an application after its filing date (see 35 U.S.C. 132(a) ). See Dart Indus. v. Banner, 636 F.2d 684, 207 USPQ 273 (C.A.D.C. 1980). See also 37 CFR 1.57(b).
MPEP 201.06(c)(IV), in-part
201.06(c) 37 CFR 1.53(b) and 37 CFR 1.63(d) Divisional-Continuation Procedure [R-08.2017]
IV. INCORPORATION BY REFERENCE
An applicant may incorporate by reference the prior application by including, in the continuing application-as-filed, an explicit statement that such specifically enumerated prior application or applications are “hereby incorporated by reference.” The statement must appear in the specification. See 37 CFR 1.57(c) and MPEP § 608.01(p). The inclusion of this incorporation by reference statement will permit an applicant to amend the continuing application to include subject matter from the prior application(s), without the need for a petition provided the continuing application is entitled to a filing date notwithstanding the incorporation by reference. For applications filed prior to September 21, 2004, the incorporation by reference statement may appear in the transmittal letter or in the specification. Note that for applications filed prior to September 21, 2004, if applicants used a former version of the transmittal letter form provided by the USPTO, the incorporation by reference statement could only be relied upon to add inadvertently omitted material to the continuation or divisional application.
An incorporation by reference statement added after an application’s filing date is not effective because no new matter can be added to an application after its filing date (see 35 U.S.C. 132(a) ). If an incorporation by reference statement is included in an amendment to the specification to add a benefit claim under 35 U.S.C. 120 after the filing date of the application, the amendment would not be proper. When a benefit claim under 35 U.S.C. 120 is submitted after the filing of an application, the reference to the prior application cannot include an incorporation by reference statement of the prior application. See Dart Indus. v. Banner, 636 F.2d 684, 207 USPQ 273 (C.A.D.C. 1980).
20.6 Confirmation of Incorporation by Reference of Elements and Parts
(a) The applicant may submit to the receiving Office, within the applicable time limit under Rule 20.7, a written notice confirming that an element or part is incorporated by reference in the international application under Rule 4.18, accompanied by:
(i) a sheet or sheets embodying the entire element as contained in the earlier application or embodying the part concerned;
(ii) where the applicant has not already complied with Rule 17.1(a), (b) or (b-bis) in relation to the priority document, a copy of the earlier application as filed;
(iii) where the earlier application is not in the language in which the international application is filed, a translation of the earlier application into that language or, where a translation of the international application is required under Rule 12.3(a) or 12.4(a), a translation of the earlier application into both the language in which the international application is filed and the language of that translation; and
(iv) in the case of a part of the description, claims or drawings, an indication as to where that part is contained in the earlier application and, where applicable, in any translation referred to in item (iii).
(b) Where the receiving Office finds that the requirements of Rule 4.18 and paragraph (a) have been complied with and that the element or part referred to in paragraph (a) is completely contained in the earlier application concerned, that element or part shall be considered to have been contained in the purported international application on the date on which one or more elements referred to in Article 11(1)(iii) were first received by the receiving Office.
(c) Where the receiving Office finds that a requirement under Rule 4.18 or paragraph (a) has not been complied with or that the element or part referred to in paragraph (a) is not completely contained in the earlier application concerned, the receiving Office shall proceed as provided for in Rule 20.3(b)(i), 20.5(b) or 20.5(c), as the case may be.
20.7 Time Limit
(a) The applicable time limit referred to in Rules 20.3(a) and (b), 20.4, 20.5(a), (b) and (c), and 20.6(a) shall be:
(i) where an invitation under Rule 20.3(a) or 20.5(a), as applicable, was sent to the applicant, two months from the date of the invitation;
(ii) where no such invitation was sent to the applicant, two months from the date on which one or more elements referred to in Article 11(1)(iii) were first received by the receiving Office.
(b) Where neither a correction under Article 11(2) nor a notice under Rule 20.6(a) confirming the incorporation by reference of an element referred to in Article 11(1)(iii)(d) or (e) is received by the receiving Office prior to the expiration of the applicable time limit under paragraph (a), any such correction or notice received by that Office after the expiration of that time limit but before it sends a notification to the applicant under Rule 20.4(i) shall be considered to have been received within that time limit.
4.18 Statement of Incorporation by Reference
Where the international application, on the date on which one or more elements referred to in Article 11(1)(iii) were first received by the receiving Office, claims the priority of an earlier application, the request may contain a statement that, where an element of the international application referred to in Article 11(1)(iii)(d) or (e) or a part of the description, claims or drawings referred to in Rule 20.5(a) is not otherwise contained in the international application but is completely contained in the earlier application, that element or part is, subject to confirmation under Rule 20.6, incorporated by reference in the international application for the purposes of Rule 20.6. Such a statement, if not contained in the request on that date, may be added to the request if, and only if, it was otherwise contained in, or submitted with, the international application on that date.
The instant application is a 371 application which has an International filing date of January 28, 2022. See a partial capture of the BIB sheet of the instant application below.
PNG
media_image4.png
468
500
media_image4.png
Greyscale
Specifically, PCT/KR2022/001548 was filed without an “incorporation by reference” statement to the earlier applications filed in Korea. Then, Applicant filed a 371 of the PCT and attempted to amend the specification to include the “incorporation by reference” statement via a Preliminary Amendment filed July 28, 2023, which is after the instant application's International filing date of January 28, 2022. This is considered new matter. MPEP 201.06(c): “An incorporation by reference statement added after an application’s filing date is not effective because no new matter can be added to an application after its filing date (see 35 U.S.C. 132(a)).”
Further, in Box VI of the PCT request form, R0/101, there is a statement regarding “incorporation by reference” which basically fulfills the written notification regarding “incorporation by reference” when the document is signed. This satisfies the written notice according to Rule 4.18 but does not satisfy the conditions of PCT Rule 20.6 (a)(i)-(iv). In the PCT, Applicant is not required to explicitly state “incorporation by reference” within the PCT Specification (description pages).
However, “incorporation by reference” in the PCT must be verified per PCT Rule 20.6 (a)(i)-(iv) for incorporating specific documents which were inadvertently left out of the PCT disclosure and Applicant has only a limited amount of time to explicitly indicate, during PCT prosecution, what the missing part(s) are and to submit those missing parts into the PCT file. Once they are in the file and if they have complied with PCT Rule 20.6 (a)(i)-(iv), the additional sheets, added by “incorporation by reference” will be stamped “incorporation by reference” by WIPO. Therefore, the entirety of the PCT application, including any missing parts added by “incorporation by reference” in the PCT prosecution will be a part of the National Stage application.
Therefore, the rules and requirements surrounding “incorporation by reference” relating to PCT are different than the “incorporation by reference” in US cases, and even if they did incorporate something by reference in the PCT e.g., a page of the specification from a foreign priority document, this does not provide them “incorporation by reference” to the entire foreign priority document. Therefore, inserting “incorporation by reference” into the disclosure on or after the National Stage US filing date would be new matter. For all the reasons given above, the “incorporation by reference” statement being added to the instant specification by way of the Preliminary Amendment is deemed new matter.
Applicant is required to cancel the new matter in the reply to this Office Action.
This objection to the specification can be overcome by deleting the sentence “The entire contents of these applications is incorporated herein by reference.” from the instant specification.
Claim Interpretation
Claims 10 and 13 claim a pharmaceutical composition comprising a compound of instant claim 1. However, no other ingredient is recited in these composition claims. Therefore, Claims 10 and 13 have been interpreted as reading on just the compound of claim 1. Prior art will be considered and applied against these claims based on this interpretation.
Claims 11 and 12 claim an inhibitor or activator which comprise a compound of instant claim 1. Claims 11 and 12 have been considered and are deemed intended use claims. The intended use (i.e., an inhibitor or activator) is not considered a limitation and is of no significance to the construction of these claims since the body of these claims describe structurally complete inventions such that deletion of the intended use language from each of claims 11 and 12 do not affect the structure of the claimed invention. Claims 11 and 12 have been interpreted as reading on just the compound of claim 1. Therefore, prior art will be considered and applied against these claims based on this interpretation.
Claim Objections
Claims 1 and 6 are objected to because of the following informalities:
in claim 1, under the definition of W5, “Cre” should be changed to “CRe” to be consistent with the definition of variable Re;
in claim 1, the 3rd line from the end of the claim, an “and” should be added at the end of the line; and
in claim 6, an “or” should be added before “an amino group” (line 3 of the claim).
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-7 and 9-13 are rejected under
35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1 is confusing because there are several valence problems in claim 1. Claim 1 claims compounds of instant Formula 1,
PNG
media_image5.png
244
272
media_image5.png
Greyscale
, which has a 9-membered bicyclic aromatic ring core comprising variables W1-W7. In instant Formula 1 in claim 1, the W1-W4 variables are defined as representing a nitrogen or a carbon substituted with a Ra-Rd variable, respectively. Additionally, each of W1-W4 is also substituted with R1-R4, respectively. There is no substitution availability on the W1-W4 variables when these variables represent a nitrogen (only 3 bonds to nitrogen) or when these variables represent a carbon substituted with a Ra-Rd variable (only 4 bonds to carbon), respectively, in the 9-membered bicyclic aromatic ring core in instant Formula 1. See, for example, the following 9-membered bicyclic aromatic ring systems which have carbon and nitrogen ring members:
triazolotetrazine,
PNG
media_image6.png
98
158
media_image6.png
Greyscale
;
4,5,6,7-tetramethyl-2H-benzotriazole,
PNG
media_image7.png
144
178
media_image7.png
Greyscale
; and 2,6,7,8,-tetramethylpurine,
PNG
media_image8.png
122
180
media_image8.png
Greyscale
.
Also, see the definitions of W5-W7 in claim 1 for same especially when the -Z-R5 moiety is attached to one of W5-W7. Therefore, claim 1 is indefinite. Correction is required.
Claim 1 is confusing because an alkenyl group and an alkynyl group each have a minimum of 2 carbons. See under the definitions of variables R6, R7, etc. wherein these variables list C1-C6 alkenyl group and/or C1-C6 alkynyl group as substituents. Therefore, claim 1 is indefinite. Correction, all occurrences, is required.
In claim 1, under the definition of R6, the phrase “or is bonded to the same carbon as carbon to A to form a 3- to 10-membered saturated ring, is bonded to the same carbon as carbon bonded to A to form a 3- to 10-membered saturated … containing at least one heteroatom of N, O and S,” is confusing as to its meaning (the 4th line from the bottom of page 4 through to line 2 of page 5). It is not clear what carbon is bonded to A or how an R6 substituent would form a ring with said carbon. Therefore, claim 1 is indefinite. Correction is required.
Claim 1 is indefinite because of a dangling valence problem since a sulfide group (-S-) and a sulfonyl group (-SO2-) are listed as possible substituents in the claim (see line 10 of page 5; and the 5th line from the bottom of page 5). The claimed compounds should not have dangling valences. Claims of the “dangling valence” type in which only the portion of the structure responsible for the activity is defined in the claim are indefinite because the claims are of indeterminate in scope and generally broader than any possible supporting disclosure. Ex parte Diamond, 123 USPQ 167 (POBA 1959). Therefore, claim 1 is indefinite.
In claim 1, there is a valence problem when the carbonyl group -(C=O)R7R8 is listed as a substituent (page 5, line 15 of the page).
Claims dependent on claim 1 which do not resolve the problems in claim 1 are also found indefinite.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-7 and 9-13 are rejected under
35 U.S.C. 102(a)(1) as being anticipated by:
the compound of PubChem CID 83681378 {National Center for Biotechnology Information. "PubChem Compound Summary for CID 83681378, 5-Methoxy-1-piperidin-4-ylbenzotriazole" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/5-Methoxy-1-piperidin-4-ylbenzotriazole. Accessed 20 January, 2026, create date October 20, 2014},
PNG
media_image9.png
200
222
media_image9.png
Greyscale
{a compound of instant Formula 1,
PNG
media_image3.png
176
206
media_image3.png
Greyscale
,
wherein
W1 is CRa where Ra is hydrogen (R1 is hydrogen);
W2 is CRb where Rb is hydrogen (R2 is hydrogen);
W3 is CRc where Rc is hydrogen (R3 is C1 alkoxy);
W4 is CRd where Rd is hydrogen (R4 is hydrogen);
W5 is N;
W6 is N;
W7 is N;
Z is absent;
R5 represents -A-(R6)y;
A represents a C5 heterocyclic group (i.e., unsubstituted piperidine); and
y is zero and R6 is hydrogen };
the compound of PubChem CID 2735464 {National Center for Biotechnology Information. "PubChem Compound Summary for CID 2735464, 1-(piperidin-4-yl)-1H-1,2,3-benzotriazole" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/1-_piperidin-4-yl_-1H-1_2_3-benzotriazole. Accessed 20 January, 2026, create date July 19, 2005},
PNG
media_image10.png
194
156
media_image10.png
Greyscale
,
{a compound of instant Formula 1,
PNG
media_image3.png
176
206
media_image3.png
Greyscale
,
wherein
W1 is CRa where Ra is hydrogen (R1 is hydrogen);
W2 is CRb where Rb is hydrogen (R2 is hydrogen);
W3 is CRc where Rc is hydrogen (R3 is hydrogen);
W4 is CRd where Rd is hydrogen (R4 is hydrogen);
W5 is N;
W6 is N;
W7 is N;
Z is absent;
R5 represents -A-(R6)y;
A represents a C5 heterocyclic group (i.e., unsubstituted piperidine); and
y is zero and R6 is hydrogen};
Bissantz et al. {US 2008/0161315} – who disclose the compound 1-(4-piperidyl)-1H-1,2,3-benzotriazole hydrochloride in paragraph [0568] on page 21 (column 2, lines 2-3),
PNG
media_image11.png
170
222
media_image11.png
Greyscale
{a pharmaceutically acceptable salt of a compound of instant Formula 1,
PNG
media_image3.png
176
206
media_image3.png
Greyscale
,
wherein
W1 is CRa where Ra is hydrogen (R1 is hydrogen);
W2 is CRb where Rb is hydrogen (R2 is hydrogen);
W3 is CRc where Rc is hydrogen (R3 is hydrogen);
W4 is CRd where Rd is hydrogen (R4 is hydrogen);
W5 is N;
W6 is N;
W7 is N;
Z is absent;
R5 represents -A-(R6)y;
A represents a C5 heterocyclic group (i.e., unsubstituted piperidine);
y is zero and R6 is hydrogen; and
the pharmaceutically acceptable salt is a hydrochloric acid salt};
and
Hembrough et al. {WO 2007/076055 A2} – who disclose Compound ENMD23-0192 on page 68,
PNG
media_image12.png
208
794
media_image12.png
Greyscale
PNG
media_image13.png
196
764
media_image13.png
Greyscale
{a compound of instant Formula 1,
PNG
media_image3.png
176
206
media_image3.png
Greyscale
,
wherein
W1 is CRa where Ra is hydrogen (R1 is hydrogen);
W2 is CRb where Rb is hydrogen (R2 is hydrogen);
W3 is CRc where Rc is hydrogen (R3 is C1 alkyl substituted with
halogens);
W4 is CRd where Rd is hydrogen (R4 is hydrogen);
W5 is N;
W6 is N;
W7 is N;
Z is absent;
R5 represents -A-(R6)y;
A represents a C5 heterocyclic group (i.e., piperidinyl)
where the C5 heterocyclic group is substituted with a carbonyl
group (-C=O)R7R8,
R7 can represent a C4 heteroaryl group (i.e., furanyl)
(note that the presence of a R8 substituent would raise a
valence problem);
y is zero and R6 is hydrogen}.
Each of the above cited prior art disclose at least one compound that is embraced by the instant claimed invention as shown above. Further, Hembrough et al. claim that his compound ENMD23-0192 modifies the activity of proteinase activated receptors when administered, either alone or with a pharmaceutically acceptable excipient or carrier, and can be used in the treatment of cancer (such as breast cancer). See claims 1, 4 and 5 on page 195 and pages 22-23 (especially line 11 on page 23) in Hembrough et al. Therefore, each of the above cited prior art anticipates the instant claimed invention.
Note to Applicant: Not every piece of prior art found in the database search or class/subclass search which would anticipate and/or render obvious the instant claimed invention under examination has been applied against the instant currently pending claims under examination. See MPEP §904.03.
Allowable Subject Matter
The elected species of Compound No. 1 is allowable over the prior art of record. The structurally closest prior art to the elected species of Compound No. 1 is the compound of PubChem CID 83681378. The elected species of Compound No. 1 is a hydrochloride salt of this PubChem compound. However, there is no utility associated with the PubChem compound. Therefore, a teaching, motivation and suggestion is lacking to make salts of the PubChem compound.
Claim 8 is objected to as being dependent upon a rejected base claim and objected to for containing withdrawn subject matter, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims and if claim 8 is limited to the identified expanded search and examination detailed above.
Reminder to Applicant
As a reminder, Applicant should specifically point out the support in the original disclosure {i.e., page number(s) and line number(s)} for any new claims or amended claims and for any amendments made to the disclosure. Making generic statements such as “all amendments are fully supported in the originally filed disclosure or the originally filed claims” without specifying page numbers and originally filed claim numbers are insufficient. See MPEP §714.02 and MPEP §2163.06(I).
Telephone Inquiry
Any inquiry concerning this communication or earlier communications from the examiner should be directed to:
Laura L. Stockton
(571) 272-0710.
The examiner can normally be reached on Monday-Friday from 8:30 am to 6 pm, Eastern Standard Time.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s acting supervisor,
James Alstrum-Acevedo can be reached on 571/272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/LAURA L STOCKTON/ Primary Examiner, Art Unit 1626 Work Group 1620
Technology Center 1600
February 17, 2026
Book XXIX, page 11